Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

GROM A. A., Ilowite N. T., PASCUAL V., BRUNNER H. I., MARTINI A., LOVELL D., ...More

ARTHRITIS & RHEUMATOLOGY, vol.68, no.1, pp.218-228, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.1002/art.39407
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.218-228
  • Hacettepe University Affiliated: Yes


ObjectiveIn pivotal trials, canakinumab has been shown to be effective in the treatment of systemic juvenile idiopathic arthritis (JIA), but reported adverse events have included macrophage activation syndrome (MAS). This study was undertaken to assess the impact of canakinumab on MAS incidence.